Abstract
Abstract On the basis of experience with calculated survivorships of patients following treatment for cancer, a simple function, in terms of two physically meaningful parameters, has been evolved, which fits such survivorship data very well. These two parameters can be used to compare succinctly the mortality of two groups, different in respect of treatment, type of cancer, or other characteristics. The parameters are c ("cured"), which represents the proportion of the population which is subject only to "normal" death rates, and β, which is the death rate from the cancer, to which the rest of the population [not "cured," (1–c)] is subject. Thus if one treatment is characterized by c 1 = 0.30, β 1 = 0.25, another by c 2 = 0.20, β 2 = 0.15, this could be interpreted as meaning that while the first treatment "cured" a larger proportion of the population than did the second treatment, it did not ameliorate the deaths attributable to cancer in the patients not cured as much as did the second treatment. If l T is the proportion of the total population surviving to time t, then the function is l T = cl 0+ (1 – c)l 0e −-βt where l 0 is the net survivorship corresponding to "normal" deaths, obtained from standard life tables. A graphic method and also a "least squares" method of estimating c and β are presented with an example, and the evaluated parameters are given for several series of treated cancer patients. Expectation of life and other functions of the life table also have been calculated from the evaluated parameters, for the same series.
Keywords
Affiliated Institutions
Related Publications
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
The oligometastatic paradigm suggests that some patients with a limited number of metastases might be cured if all lesions are eradicated. Evidence from randomised controlled tr...
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial
Lobectomy is the standard of care for early-stage non-small-cell lung cancer (NSCLC). The survival and clinical benefits of segmentectomy have not been investigated in a randomi...
Components of early intervention outpatient palliative care consultation in patients with incurable NSCLC
e20635 Background: Many experts recommend palliative care consultation early in the course of oncology treatment; however little is known about the components of this type of in...
Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial
Screening for prostate cancer using prostate-specific antigen (PSA) reduces prostate cancer mortality but can lead to adverse outcomes. We aimed to compare a traditional screeni...
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patien...
Publication Info
- Year
- 1952
- Type
- article
- Volume
- 47
- Issue
- 259
- Pages
- 501-515
- Citations
- 811
- Access
- Closed
External Links
Social Impact
Social media, news, blog, policy document mentions
Citation Metrics
Cite This
Identifiers
- DOI
- 10.1080/01621459.1952.10501187